WebFeb 14, 2024 · CSL (CSL) has completed its $750 million share purchase plan (SPP), following its $6.3 billion placement. Last year, the company announced its plans to raise the money to buy Switzerland-based Vifor … WebCSL’s ADR information with BNY Mellon can also be viewed at www.bnymellon.com. ADR holders seeking information on their shareholding should contact: BNY Mellon …
CFO helps CSL nail record $6.3b raise in 24 hours
WebCSL’s offer is a 40% premium to the undisturbed Vifor Pharma share price from the 60 days prior to December 1. Vifor Pharma’s share price had increased in the past two weeks as speculation about a takeover emerged. The Switzerland-based company largest shareholder Patinex AG, which owns 23.2% of the company, has agreed to the deal. WebThe listing price of $273 per share sees about 23.1 million new CSL shares brought onto its registry. The company also launched a $750 million share purchase plan, offering the same terms to ... eastchem sp. z o.o
CSL shares on offer at a discount ahead of acquisition
WebBuy CSL Shares. CSL Ltd (CSL) is a leading biotechnology business based in Australia. It opened the day at AUDA$285.99 after a previous close of AUDA$285.5. During the day the price has varied from a low of AUDA$285.32 to a high of AUDA$288.36. The latest price was AUDA$288.3 (25 minute delay). CSL is listed on the Australian Securities ... WebThe Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can … WebDec 14, 2024 · Total acquisition consideration based on offer price of US$179.25 per share, fully diluted shares on issue of 65 million, and debt of CHF 540 million. Excludes transaction costs. 4. CSL will also undertake a non-underwritten Share Purchase Plan ("SPP") to eligible CSL shareholders. The SPP is targeting to raise up to A$750 million. cube agree c62 2017